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Abstract
Background: Lateral elbow tendinopathy (LET) is a common condition affecting adults. Although a lack of treatment
consensus continues to prompt numerous effectiveness studies, there is a paucity of clear guidance on the choice of
outcome measure. Our aim was to undertake a standardised evaluation of the available clinical rating systems that
report patient-centred outcomes in LET.
Methods: A systematic review of studies reporting the development, assessment of metric properties and/or use of
instruments aiming to quantify LET-specific patient-centred outcome measures was conducted in MEDLINE, Embase
and CINAHL (inception-2017) adhering to PRISMA guidance. The evidence for each instrument was independently
assessed by two reviewers using the standardised evaluating measures of patient-reported outcomes (EMPRO) method
evaluating overall and attribute-specific instrument performance (metric properties and usability). EMPRO scores
> 50/100 were considered indicative of high performance.
Results: Out of 7261 references, we identified 105 articles reporting on 15 instruments for EMPRO analysis. Median
performance score was 41.6 (range 21.6–72.5), with four instruments meeting high-performance criteria: quick
Disabilities of the Arm Shoulder and Hand score (qDASH) (72.5), DASH (66.9), Oxford Elbow Score (OES) (66.6) and
Patient-Rated Tennis Elbow Evaluation (PRTEE) (57.0). One hundred seventy-nine articles reported instrument use
internationally with DASH as the most frequent (29.7% articles) followed by PRTEE (25.6%), MEPS (15.1%) and qDASH
(8.1%). The correlation between frequency of use and performance was r = 0.35 (95%CI − 0.11; 0.83).
Conclusions: This is the first study to provide standardised guidance on the choice of measures for LET. A large number
of clinical rating systems are both available and being used for patients with LETs. Robust evidence is available for four
measures, the DASH, QDASH, PRTEE and OES. The use of instruments in the literature is only in part explained by
instrument performance.
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Key Points
 There are 15 clinical rating systems used in the
literature that aims to quantify the patients’
experience of lateral elbow tendinopathy. Adequate
evidence of their validity is only available for four of
those 15 clinical ratings systems.
 Within the literature, the choice of the clinical
rating system has not been associated with its
quality.
Background
Lateral elbow tendinopathy (LET), known commonly as
tennis elbow, is a highly prevalent and painful condition
affecting the lateral side of the elbow [1]. The exact
aetiology and pathogenesis are currently unknown and
are the source of much debate [2–7], but some element
of overuse of the common forearm extensors is believed
to be implicated. Patients experience a broad spectrum
of symptoms, from mild self-limiting pain that responds
to activity modification and simple analgesia, to debili-
tating pain on the outer elbow, spreading down the
forearm, which leads to loss of function of the affected
limb [1]. At its worst, LET can have a major impact on
an individual’s social and professional life [8, 9].
The general population prevalence of LET is between
1% and 3% [10], rising in those with occupational risk fac-
tors to as high as 41% [11]. Men and women are equally
affected and onset peaks at approximately 40–50 years
[12, 13]. Although this condition is usually self-limiting,
symptoms persist for over 1 year in up to 20% of people,
and in 8.5%, symptoms recur within 2 years [14]. Up to
5% of LET patients claim sickness absence, at an average
duration of 29 days per year [15]. In the UK in 2012, lost
earnings through absenteeism from LET was estimated to
cost £27 million [16].
There is no consensus on the optimal management of
LET [17]. Though a vast quantity of options exists, large
systematic evaluations continue to find deficits in the
evidence base for many interventions [10]. Recommen-
dations for future research include conducting large-scale,
good quality randomised controlled trials (RCTs) that uti-
lise validated outcome measures [1, 10, 13, 18]. Histori-
cally, outcomes in LET focused on clinical examination
findings; however, recent emphasis in health technology
assessment has shifted to focus on quantifying the
patients’ perspective on how their condition affects
their life.
In an effort to capture the effect of health interven-
tions on patients, there has been a considerable invest-
ment of resources by academics and clinicians to
develop standardised, robust and valid ways of collecting
patient-centred outcomes, typically collected through
clinical rating systems that are either patient-reported
outcome measures (PROMs) or clinician-reported out-
comes measures (CROMs), sometimes also combining
both approaches [19]. Their choice and use must be sup-
ported by published evidence demonstrating that they are
acceptable to patients, reliable, valid and responsive (sensi-
tive to change) [20]. Furthermore, in an effort to bring
further standardisation across research and clinical ap-
plications, clinical rating systems are also being inte-
grated into core outcome sets, with influential groups
including the Core Outcome Measures in Effectiveness
Trials (COMET) and International Consortium for
Health Outcomes Measurement (ICHOM) placing par-
ticular emphasis on a systematic approach to instru-
ment choice.
The 2013 review by The et al. [21] represents the only
previous attempt at a standardised assessment of elbow
specific measures. They included 12 outcome measures
using the Consensus-Based Standards for the Selection
of health Measurement Instruments (COSMIN) check-
list which concluded that the Oxford Elbow Score (OES)
was developed using the highest quality methodology.
However, for certainty of use, the performance of clinical
rating systems needs to be assessed specifically for the
condition of interest. As The et al. comment, it is essen-
tial to be aware that established validity characteristics
might not be applicable when using the rating system in
a different population. Therein, a rating system originally
designed for the assessment of elbow joint arthroplasty
may not be appropriate for use in LET, unless evidence
of performance has been explicitly presented. Further-
more, a narrow focus on elbow specific instruments
neglects the possibility that region-specific (i.e. upper
limb) instruments may have been robustly assessed for
certain pathologies. Finally, reviews of measures with a
region/anatomical location perspective disregard the
very different characteristic clinical presentations of dif-
ferent conditions and may advise on the use of measures
that works best across conditions, but not necessarily
the best option for any given condition.
To our knowledge, no systematic review has previously
identified the clinical rating systems for patients with LET
and assessed both their use in the scientific literature and
their performance against validated standards, both to
establish what instruments offer the best performance and
whether these are indeed the ones most widely used. This
study aims to apply a standardised system to evaluate evi-
dence available on the metric properties, development
process and utility of clinical rating systems assessing
patient-centred outcomes in LET.
Methods
Systematic Review
We conducted a systematic review of published studies on
the development and/or use of clinical rating systems in
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patients with LET. This systematic review was registered
with the PROSPERO International prospective register of
systematic reviews (PROSPERO 2016:CRD42016037317),
and the present report has been written following
PRISMA guidelines [22].
A search strategy was constructed using MeSH and
free-text terms (Additional file 1) (available at http://me
dicine.exeter.ac.uk/research/healthserv/healthservicesandp
olicy/projects/proms/optimisinginterventionaltreatmentof
tenniselbow/elbowoutcomemeasures/#d.en.504281).
The search strategy development was guided by pre-
viously published strategies for systematic reviews of
interventions in LET [23] and for the identification of
outcome measures [24]. Known condition-specific mea-
sures were identified and incorporated into the strategy
through the assessment of previous systematic reviews
of elbow-specific rating scales [21, 25–27], and search of
the online library of patient-reported outcomes and
quality of life database (PROQOLID) [28].
The strategy was tailored to each database through the
modification of thesaurus terms, wildcards and trunca-
tions. The search was first run on 1 May 2017 in Medline
(Ovid MEDLINE, 1948 to 2017 & Ovid MEDLINE
In-Process & Non-Indexed Citations) accessed through
OVIDSP, Embase (Embase 1974 to 2017) accessed
through OVIDSP and CINAHL (CINAHL 1981 to 2017).
Further searches of the Cochrane Central Register of Con-
trolled Trials (CENTRAL), thesis searching via ProQuest
and the Kings Fund library database were undertaken.
The resulting references were retrieved and imported
into a bibliographic database using reference manager
software (Endnote X7). Duplicates were removed.
All articles reporting the development, psychometric
evaluation or use of English language clinical rating
systems in LET in adults (> 18 years) were included.
In instances where the study included multiple elbow
pathologies, it had to specify that this comprised, at
least in part, a population of LET patients. Multi-item
upper limb or elbow-specific instruments that were
either clinician or patient-led were included.
Study selection utilised a step-wise approach. Screening
was conducted by two reviewers at all stages. To ensure
the highest levels of sensitivity, in cases of disagreement,
the study proceeded to the next step for more in-depth
assessment. Reviewer comprehension of the research aims
was assessed using a 20-study pilot, achieving an inter-
rater agreement (kappa) of 0.85. Title and abstracts were
disseminated to the reviewers using the web and mobile
application software Rayyan (Doha, Qatar) which allows
collaborators to remotely screen the articles [29]. Full-text
assessment was undertaken using hard copy manuscripts.
Studies were excluded if reporting case studies, case
reports, surgical technique papers, conference abstracts
and manuscripts not in the English language. Forward and
backward searches were undertaken on full-text manu-
scripts using Scopus® (Elsevier B.V.). Instrument manuals,
complementary support material and cross-check of refer-
ence lists were sourced via the instruments’ associated
website or in direct contact with the developer.
Due to the principles of cross-cultural adaptation, the
metric properties of an instrument are not directly com-
parable across different versions. Hence, only full texts of
instruments developed or tested in the English speaking
populations were included in the evaluating measures of
patient-reported outcomes assessment (EMPRO) [30]. By
convention, the instruments were identified by their name
and acronym, when one had been given or by the name of
the first author in the seminal paper, and the clinical
rating systems were classified as either PROMs, pure
CROMs and mixed PROMs/CROMs.
Evaluating Measures of Patient-Reported Outcomes
(EMPRO)
The EMPRO tool [30] was developed to measure the
performance of patient-centred outcomes for informing
the identification of the best candidates among measures
competing for the same purpose. Originally designed for
PROMs, the content, structure and methodology are apt
for the evaluation of all clinical rating systems. It has
been utilised in a number of areas, including assessment
of shoulder outcome instruments [31] and there is good
evidence for its validity and reliability [30]. Its particular
strength includes the synthesis of the whole body of
evidence surrounding an outcome instrument and its
ability to facilitate the selection of the most appropriate
outcome instrument [30]. Unlike the COSMIN checklist,
it does not evaluate the quality and design of the eva-
luation of the psychometric properties but rather the
performance of the instrument.
EMPRO consists of eight scales measuring the follow-
ing attributes each: conceptual and measurement model
(7 items), reliability (8), validity (6), responsiveness (3),
interpretability (3), administrative burden (7), alternative
modes of administration (2) and cross-cultural adap-
tations into chosen reference language (3). Each item
consists of a short statement, together with suggested
aspects to be considered. Reviewers then express their
agreement on an ordinal Likert-type response scale of
1–4. Where appropriate, ‘not applicable’ and ‘no infor-
mation available’ response categories are available. At
the end of the tool, reviewers are requested to provide
an overall recommendation [30] (Table 1).
Each instrument was evaluated independently by two
researchers using the EMPRO tool and based on the
following information:
 The instrument to be assessed
 The instrument’s user manual (where available)
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 Full text of all publications which provide
information concerning the development process,
the metric properties or the administration of the
instrument including a sample which, at least in
part, contains participants with LET.
The researchers were experts in outcomes research,
they received additional training in the use of the
EMPRO, and none of them had been involved in the
development of the reviewed measures. EMPRO scores
were consolidated and tabulated. Where discrepancy in
scores existed, the two reviewers initially discussed the
case to resolve through consensus, where necessary a
third reviewer opinion was sought.
Analytic Strategy
Attribute specific scores were calculated as the response
mean of the applicable items. Items for which the
response was ‘no information’ were assigned a score of 1
(lowest possible). This raw mean was linearly trans-
formed to scale the scores from 0 (worst possible) to
100 (best possible).
From the attribute scores, an overall attribute mean
score was calculated. The scores of the five attributes
that relay the psychometric-related information (concep-
tual and measurement model, reliability, validity, sensi-
tivity to change and interpretability) were included. The
overall attribute score was only calculated when at least
three of the five attributes had a score. EMPRO overall
attribute scores for each outcome instrument are consi-
dered adequate if they reach at least 50 out of the
maximum score of 100 [30].
Agreement between reviewers was assessed using a
weighted Cohen’s kappa coefficient. All analysis was
undertaken in STATA (2015. Release 14. College Station,
TX: StataCorp LP). Databases of instruments’ distri-
bution were managed in MS Excel (2013, Redmond, WA:
Microsoft®). Kappa scores and resource numbers are
displayed as median (interquartile range (IQR)) range).
Spearman’s correlation coefficient was used to assess the
relationship between EMPRO score and proportional use
of the instrument within the literature.
Results
The review search strategy identified 7261 articles
(Fig. 1). Following duplicate removal, 6185 articles were
reviewed at the title level. After evaluation of references
screened as full texts, 15 clinical rating scales were iden-
tified (Table 2).
Assessment of the instruments’ reported use in LET
studies found four instruments to be reported much
more frequently than the remaining 11 (Fig. 2). The
Disabilities of the Arm Shoulder and Hand (DASH)
score was the most frequently reported (29.7% of arti-
cles), followed by the Patient-Rated Tennis Elbow Evalu-
ation (PRTEE) (25.6%), Mayo Elbow Performance Score
(15.1%) and quick Disabilities of Arm Shoulder and
Hand (qDASH) (8.1%). Over time, this trend has shifted
with the reporting of these scores increasing over time.
Table 1 EMPRO attributes definition, number of items and scoring description (adapted from Garin et al. [36]). KR-20 Kuder-
Richardson 20, EMPRO evaluating measures of patient-reported outcomes
Attribute Definition No.
of
items
Higher scores represent…
Conceptual and
measurement
model
The rationale for and description of the concept and the
populations that a measure is intended to assess and the
relationship between these concepts
7 The concept is more clearly stated to be measured. The
empirical basis and methods for obtaining the item and for
combining them are more appropriate
Reliability The degree to which an instrument is free from random
error
8 More clearly described and superior methods to collect internal
consistency data. Better values of Cronbach’s alpha and/or
KR-20 coefficients
Validity The degree to which the instrument measures what it
purports to measure
6 More evidence regarding content-related validity of the
instrument for its intended use
Responsiveness An instrument’s ability to detect change over time 3 More clearly described and more appropriate methods to
assess sensitivity to change. The estimated magnitude of
change is more clearly described, and the results are better
Interpretability Possibility of assigning meaning to quantitative scores 3 The strategies to facilitate interpretation are more clearly
described and appropriate
Burden The time, effort and other demands placed on those to
whom the instrument is administered (respondent burden)
or on those who administer the instrument (administrative
burden)
7 The skills and time to complete the instrument are more
clearly described and acceptable
Alternative
modes of
administration
Alternative modes of administration used for the
administration of the instrument
2 The metric characteristics and use of each alternative mode of
administration are specifically described and adequate
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Of note, of the 179 articles in the international literature,
40 (22.3%) reported two using two or more clinical rat-
ing systems to assess patient-centred outcomes. Within
the 179 articles, 155 reported the results of clinical ef-
fectiveness research, 36 (23.2%) of which were surgical,
117 (75.5%) were non-surgical and 2 (1.3%) compared
surgical and nonsurgical modalities. Differences were
noted in the proportional use of the most common out-
come measures (DASH, PRTEE, MEPS and qDASH)
within the surgical (41.7%, 8.3%, 25% and 5.6%, respect-
ively) and non-surgical group (28%, 23%, 7.7% and
7.7%).
Clinical Rating Systems
Of the 15 outcome clinical rating systems, six were
PROMs, six were CROMs, and the remaining three
included both clinician and patient-reported information
(Table 2).
The instruments had been developed between 1979
and 2008. Four instruments had been designed specifi-
cally for the assessment of LET: Patient-Rated Tennis
Elbow Evaluation (PRTEE), Nirschl score, Tennis Elbow
Functional Scale (TEFS) and Verhaar score. Three more
instruments had been designed as elbow-specific across
different pathologies: American Society of Shoulder and
Elbow Surgeons-Elbow (ASES-E), Liverpool Elbow Score
(LES) and Oxford Elbow Score (OES). Three other
instruments (DASH, qDASH and the Upper Limb Func-
tional Index (ULFI)) are region-specific (upper limb),
and the remaining five instruments had been designed
for the assessment of other pathologies (e.g. arthroplasty,
radial head fracture) but have been used in the
assessment of LET outcomes.
Psychometric Evaluation
All instruments were assessed using the EMPRO meth-
odology (Additional file 2). The volume of resources
informing each EMPRO assessment averaged four arti-
cles (IQR 8.5) (range 1–41) (Table 2).
Concordance between individual EMPRO evaluations
was moderate to substantial in all cases, kappa median
0.72 (IQR 0.36) (range 0.47–0.94) [32]. Resolution of
score differences was achieved by consensus in all cases.
The overall summary scores ranged from 72.5 (qDASH) to
21.6 (ASES-E). Only four instruments met the threshold
score of 50/100: one LET specific (PRTEE), one elbow spe-
cific (OES) and two upper-limb specific (qDASH and
DASH). It was not possible to calculate the overall scores
for the Morrey, Andrews and Carson, Roles and Maudsley,
Hospital for Special Surgery score (HSS), Nirschl and
Verhaar instruments because of a lack of available evidence
(Fig. 3).
Fig. 1 PRISMA flowchart of systematic literature review. Review of articles reporting development/metric properties or use of outcome
instruments. LET lateral elbow tendinopathy, EMPRO evaluating measures of patient-reported outcomes
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Whereas no reviewer ‘strongly recommended’ any of the
outcome instruments, qDASH, DASH, OES and PTREE
were all ‘recommended (with provisos or alterations)’. Of
those instruments, recommendations of use extended only
to group comparison of a general adult population rather
than individual monitoring, owing to lack of clear respon-
siveness data in LET patients.
The Spearman correlation coefficient between overall
performance and frequency of use in the literature was r
= 0.35 (95%CI − 0.11; 0.83).
Discussion
This study identified 15 clinical rating systems that, to
varying degrees, attempt to assess patient outcomes in
individuals suffering from LET. All 15 clinical rating sys-
tems were systematically evaluated in view of their de-
velopment, metric properties and history of use within
the LET literature. Of those instruments, only four met
both the overall attribute benchmark score of 50 and
overall recommendation of the reviewers, to suggest that
their use can be justified in the evaluation of LET. This
study has gone a step further than previous elbow-spe-
cific outcome instrument evaluations [21, 25, 33–35] in
attempting to systematically compare the instruments in
a condition-specific context. Furthermore, it is the first
to attempt to quantify both the properties of the
instruments and the instruments’ distribution of use
within the literature, which both feature significantly in
the researcher’s or clinician’s mind when choosing a tool.
From this assessment, we would recommend authors of
future studies of LET participants, where English
language instruments will be used, consider the qDASH,
DASH, OES or PRTEE. Furthermore, summary tables
from the EMPRO evaluation (Additional file 3) can be
used to guide instrument choice when the quantification
of a particular attribute is desirable. For example, if the
responsiveness in longitudinal studies is a priority, we
would recommend the qDASH or PRTEE; for minimised
Fig. 2 The change in the percentage of use of outcome instruments over time. A&C Andrews and Carson, ASES-E American Shoulder and Elbow
Score-E, DASH Disabilities of the Arm Shoulder and Hand, HSS Hospital for Special Surgery, LES Liverpool Elbow Score, MEPS Mayo Elbow
Performance Score, OES Oxford Elbow Score, PRTEE Patient-Rated Tennis Elbow Evaluation, qDASH quick Disabilities of the Arm Shoulder and
Hand, R&M Roles and Maudsley, TEFS Tennis Elbow Functional Score, ULFI Upper Limb Functional Index
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administrative burden, we would recommend the OES;
if the inclusion of specific dimensions such as psycho-
social effect was desired, we would recommend the OES.
This presentation of condition-specific quality may also
reduce the 22% of studies that utilise two or more clin-
ical rating systems, with its consequent burden on the
study participants.
To the authors’ knowledge, this is the first upper-limb
specific study that has quantified the condition-specific
quality of the instrument, and formally identified instru-
ments’ distribution of use. Previous EMPRO evaluations
have found concordance between the quality of the in-
struments and their history of use [36]. Though there is
some agreement between quality and use of instruments
in LET, instruments are being widely used although the
evidence for their metric properties is significantly lim-
ited compared to alternatives. Whilst the results of our
standardised evaluation would support the common use
of the DASH and PRTEE, it is surprising that the
qDASH and OES are used so infrequent. Furthermore, it
is concerning that the Mayo Elbow Performance Score
(MEPS), which did not meet our minimum benchmark,
is used twice as often as the qDASH and seven times
more often than the OES. This trend, which has not
changed significantly over time, would appear to be
more prevalent within the surgical rather than
non-surgical literature. The qDASH is the abbreviated
version of the DASH and scored more highly than the
full version owing to a more compelling record of
validation in LET populations. Although it is becoming
increasingly popular, it is still only utilised in a minority
(14.6%) of contemporary LET studies.
High-Performing Instruments
The qDASH, DASH, OES and PTREE exceeded the mini-
mum criteria for recommendation. Of note, both the
qDASH and DASH scored > 50 on every attribute-specific
score. Of these four measures, particular strengths
(identified as a particular metric attribute-specific score
> 80/100), were the conceptual development of the OES
and responsiveness of the qDASH. The OES developed
its items with patient groups and expert panels, using a
high-quality methodology; however, it is worth noting
that due to the unidimensional nature of the resulting
instrument, composite scores are not advised, a fact
ignored in many subsequent studies using the score.
Fig. 3 Attribute specific and overall EMPRO scores. 0 (worst) to 100 (best). A&C Andrews and Carson, ASES-E American Shoulder and Elbow
Score-E, DASH Disabilities of the Arm Shoulder and Hand, HSS Hospital for Special Surgery, LES Liverpool Elbow Score, MEPS Mayo Elbow
Performance Score, OES Oxford Elbow Score, PRTEE Patient-Rated Tennis Elbow Evaluation, qDASH quick Disabilities of the Arm Shoulder and
Hand, R&M Roles and Maudsley, TEFS Tennis Elbow Functional Score, ULFI Upper Limb Functional Index, EMPRO evaluating measures of
patient-reported outcomes
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The responsiveness of the qDASH has been comple-
mented by studies containing considerable proportions
of LET patients [37, 38]; however, it is worth noting
that the DASH, OES and PRTEE all scored well in this
attribute. The condition-specific PRTEE, though re-
liable, valid and responsive, was developed without
clear patient involvement. Factor analysis, where the
number of fundamental dimensions that underlie the
observed data is analysed statistically in a large dataset,
in order to rationalise the questionnaire structure
has not been reported, and the justification of visual
numeric scales is not clear.
Areas where further data could enhance these scores
include assessment of metric properties in isolated LET
groups for the qDASH, DASH and particularly the
further assessment of condition-specific construct validity
of the OES. Furthermore, future studies focusing on the
interpretability would benefit from a LET-specific der-
ivation of minimal change scores through the use of
either accepted distribution-based or anchor-based
methodologies, which would strengthen this specific
attribute considerably.
Other Instruments
The TEFS, ULFI, LES, MEPS and ASES-E scored below
the minimum criteria for recommendation. Though the
TEFS is a condition-specific score, the reporting of its
metric properties has only occurred in a University
Master’s thesis published in 1999 [39]. However, it has a
history of use in peer-reviewed publications as recently
as 2012. Though scoring well for reproducibility, the
weight of evidence for the remaining metric properties
currently precludes its recommendation. The ULFI is a
generic upper limb score with a history of use in LET,
and although conceptually well designed and responsive,
the lack of information on its metric properties within a
condition-specific context precludes its recommen-
dation. The LES is a robustly designed instrument that
has been employed in LET studies; however, a significant
lack of data on the instrument’s responsiveness and
interpretability hugely hamper the instrument’s utility to
the researcher. The MEPS is a commonly used instru-
ment; within the LET literature, it is reported in 15% of
studies. However, this tool was never designed for appli-
cation in LET, and consequently, its domain structure
may not reflect the experience of LET patients. The lack
of data across all metric aspects highlights that this is
likely to be an unsuitable instrument, yet its use appears
to be increasing over time. The particular lack of data
on the instrument’s interpretability in the context of
LET exemplifies that though this is historically popular,
researchers may struggle to justify its use. A similar
scenario is present for the ASES-E score, which again
lacks metric details in LET populations.
The remaining instruments scored below the required
three out of five attribute scores for calculation of a
composite score. They were all developed prior to 1986
and are clinician-rated. The lack of data on all of their
metric properties implies that their use does not stand
up to modern reporting requirements of outcome
instruments [40, 41]. This is pertinent information due
to the continued reporting of these instruments in con-
temporary literature.
This systematic review has focussed on the validity of
condition-specific clinical rating scales, but it should be
noted that the use of global impression scales or generic
PROMs remains recommended as an adjunct. Although
no history of explicit LET based validation has been
undertaken, the use of such instruments as visual ana-
logy pain and function scales or generic measures such
as the 36-item Short Form survey (SF-36) or EuroQol
5-Dimension survey (EQ-5D) allows flexibility in results
interpretation as they act as a common currency that
allows aggregation and comparison across patient groups
and health services, whilst the LET-specific rating scale
imparts the detailed picture of a patient’s assessment of
his/her own health [19].
Limitations
This systematic review should be interpreted with refe-
rence to limitations inherent to its methodology. Firstly,
our results are dependent on the information retrieved
from the search strategy. It is important to note that the
strategy was developed with reference to extensive proto-
cols, and the largest health science databases (MEDLINE,
Embase and CINAHL) were utilised and complemented
with the addition of thesis searching and hand searching
in recognised repositories. Furthermore, authors of the
identified instruments were contacted and asked to
confirm whether the list of manuscripts identified was
as comprehensive as possible. Nevertheless, inherent
in all search strategies is the possibility of missed or
omitted evidence.
Secondly, the choice of the EMPRO tool itself should
be scrutinised. Multiple attempts have been made to
quantify the strength of evidence surrounding a set of
instruments. The EMPRO tool was used owing to its
emphasis on assessing the whole body of evidence relat-
ing to an instrument. We feel the validated output of a
‘score’ and recommendation is very beneficial to the
clinician and researcher. The authors recognise that
this may be complemented with the addition of the
commonly cited COSMIN, which would scrutinise the
methodological quality of the studies assessing the
metric properties, rather than the instrument itself.
This approach may be complementary, but to our
knowledge, this method has not yet been reported.
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Thirdly, it is recognised that our use of English
language tools only limits the generalisability of our
findings. However, we feel that the use of both non-Eng-
lish language instruments and data derived from
cross-culturally adapted instruments imparts variables that
the EMPRO tool was not conceived to deal with. Where
the EMPRO provides comparative scores across instru-
ments, the addition of information derived from a different
cultural context is unhelpful for the researcher/clinician.
Where adaptation of a tool is undertaken, certain aspects
of its metric properties cannot be compared and should
not be collated to complement the body of evidence
[41, 42]. Strictly speaking, though all of the instruments
were developed in the English language, the use of data
from different English-speaking countries could be
questioned. However, this group has identified that
currently, pathology-specific and country-specific data
for LET is not prevalent enough to allow such specific
analysis. We would hope that the presented data
encourage the exploration of culturally specific metric
properties that would allow a detailed country-specific
analysis in the future.
Fourthly, beyond the assessment of LET specific stud-
ies, this assessment derived some information from stud-
ies that contained a component of non-LET participants
(Table 2). Therefore, contamination of our findings is
possible as, in many instances, it is not possible to quan-
titatively extract the LET information and assess it in
isolation from other pathologies. Here a pragmatic
assessment was required to assess the psychometric
strengths and weaknesses of the clinical rating system in
the mixed cohort in which it is presented. Where
possible, isolated subgroup analyses were taken as the
predictive marker of psychometric performance, but this
has to be tempered with the reduction of sample size in
a mixed cohort. The authors feel that at present, though
pathology-specific advice is highly sought after, it is a
significant challenge in musculoskeletal health owing to
the traditional use of region or joint-specific instru-
ments. We advise our methods as a best possible route
but would recommend that the reporting of pathology-
specific details in all future development or assessment
of musculoskeletal PROMs instruments will greatly
enhance this process.
Future
We hope that the presentation of information on both
quality and distribution of use will compel researchers
to carefully consider their instrument choice. Though
this study reports the current strengths and weaknesses
of LET instruments, it is important to comment on the
changing landscape of outcome measure assessment in
upper limb pathology. New novel instruments have been
developed that integrate both patient-reported PROMs
assessment and patient-reported objective function, in-
cluding the German language Elbow Self-Assessment
Score (ESAS) [43]. There is also an emergence of
computer-based systems that use predictive algorithms
to administer streamlined PROMs, easing data collection
and analysis and decreasing participant burden. These
systems offer great potential but are in the early stages
of use in upper limb pathology [44]. Of note, the
Patient-Reported Outcomes Measurement Information
System (PROMIS), developed by the National Institutes
of Health, is the largest computer-adaptive testing sys-
tem but has no history of validation for the elbow region
or specific elbow pathologies [44].
Conclusion
This study is the first to provide a systematic evaluation
of LET-specific PROMS instruments. The available evi-
dence would currently support the use of the qDASH,
DASH, PRTEE or OES instruments. Though the qDASH
scored highest, we would advise that the choice of in-
strument should also depend upon the study’s particular
requirements. We hope that the evidence presented for
each metric attribute will facilitate the selection process.
Future instrument development, particularly for those
not meeting the recommended standards, can also be
rationalised from the presented evidence. It is now
clearly recognised that the choice of outcome instru-
ment must be justified from both a validity and burden
standpoint.
Additional Files
Additional file 1: Search strategy. (DOCX 424 kb)
Additional file 2: List of included manuscripts identified and used in
systematic assessment (DOCX 424 kb)
Additional file 3: EMPRO attribute and individual item scores for each
outcome instrument. Item scores graded from 4 (strongly agree) to 1
(strongly disagree or no information). (DOCX 33 kb)
Abbreviations
ASES-E: American Society of Shoulder and Elbow Surgeons-Elbow;
COMET: Core Outcome Measures in Effectiveness Trials; COSMIN: Consensus-
Based Standards for the Selection of health Measurement Instruments;
CROM: Clinician-reported outcome measure; DASH: Disabilities of the Arm
Shoulder and Hand; EMPRO: Evaluating measures of patient-reported out-
comes; ESAS: Elbow Self-Assessment Score; HSS: Hospital for Special Surgery
Score; ICHOM: Consortium for Health Outcomes Measurement;
IQR: Interquartile range; LES: Liverpool Elbow Score; LET: Lateral elbow
tendinopathy; MEPS: Mayo Elbow Performance Score; OES: Oxford Elbow
Score; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-
Analyses; PROM: Patient-reported outcome measure; PROQOLID: Patient-
Reported Outcomes and Quality of Life Database; PRTEE: Patient-Rated
Tennis Elbow Evaluation; qDASH: quick Disabilities of the Arm Shoulder and
Hand; RCT: Randomised controlled trial; TEFS: Tennis Elbow Functional Scale;
ULFI: Upper Limb Functional Index
Acknowledgements
Not applicable
Evans et al. Sports Medicine - Open            (2019) 5:10 Page 11 of 13
Funding
The authors have no funding to declare. The corresponding author (J Evans)
was supported by the National Institute for Health Research (NIHR)
Collaboration for Leadership in Applied Health Research and Care South
West Peninsula (NIHR CLAHRC South West Peninsula). The views expressed
are those of the author(s) and not necessarily those of the NHS, the NIHR or
the Department of Health and Social Care.
Availability of Data and Materials
Source data can be found in the manuscript appendices and further raw
review data can be found at https://doi.org/10.6084/m9.figshare.7028240.v1
Authors’ Contributions
JPE was responsible for study concept, design, screening, data extraction,
data analysis and writing of the manuscript. IP, JG, CB, AD and NF were
responsible for screening, data extraction and review of the manuscript. CS,
VG and JV were responsible for study concept, design and writing of the
manuscript. All authors read and approved the final manuscript.
Ethics Approval and Consent to Participate
As a systematic review, ethical approval was not sought in line with our
institutional guidance.
Consent for Publication
No individual personal data requiring consent for publication is contained
within this manuscript.
Competing Interests
The authors, Jonathan Evans, Ian Porter, Jaheeda Gangannagaripalli, Charlotte
Bramwell, Antoinette Davey, Chris Smith, Nicola Fine, Vicki Goodwin, and
Jose Valderas, declare that they have no competing interest relevant to the
content of this review.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Health Services and Policy Research Group, University of Exeter Medical
School, Exeter, UK. 2Royal Devon and Exeter NHS Foundation Trust, Exeter,
UK. 3National Institute for Health Research (NIHR) Collaboration for
Leadership in Applied Health Research and Care (CLAHRC) South West
Peninsula, University of Exeter Medical School, Exeter, UK.
Received: 5 October 2018 Accepted: 6 March 2019
References
1. Ahmad Z, Siddiqui N, Malik SS, Abdus-Samee M, Tytherleigh-Strong G,
Rushton N. Lateral epicondylitis: a review of pathology and management.
Bone and Joint Journal. 2013;95-B(9):1158–64.
2. Morrey ME, Dean BJF, Carr AJ, Morrey BF. Tendinopathy: same disease
different results—why? Oper Tech Orthop. 2013;23(2):39–49.
3. Zeisig E. Natural course in tennis elbow—lateral epicondylitis after all? Knee
surgery, sports traumatology. Arthroscopy. 2012;20(12):2549–52.
4. Morrey BF, Sanchez-Sotelo J. The elbow and its disorders: Elsevier health
sciences; 2009.
5. Dean BJF, Gettings P, Dakin SG, Carr AJ. Are inflammatory cells
increased in painful human tendinopathy? A systematic review. Br J
Sports Med. 2016;50(4):216–20.
6. Cook JL, Purdam CR. Is tendon pathology a continuum? A pathology model
to explain the clinical presentation of load-induced tendinopathy. Br J
Sports Med. 2009;43(6):409–16.
7. Rees JD, Stride M, Scott A. Tendons–time to revisit inflammation. Br J Sports
Med. 2014;48(21):1553-7.
8. De Smedt T, de Jong A, Van Leemput W, Lieven D, Van Glabbeek F. Lateral
epicondylitis in tennis: update on aetiology, biomechanics and treatment.
Br J Sports Med. 2007;41(11):816–9.
9. Council TIIA. Epicondylitis and occupational activity. In: Council TIIA, editor.
gov.uk/iiac: Department of Work and Pensions, UK; 2015.
10. Long L, Briscoe S, Cooper C, Hyde C, Crathorne L. What is the clinical
effectiveness and cost-effectiveness of conservative interventions for
tendinopathy? An overview of systematic reviews of clinical effectiveness
and systematic review of economic evaluations. Health Technol
Assess(Winchester, England). 2015;19(8):1–34.
11. Özdolap Ş, Emre U, Karamercan A, Sarikaya S, Köktürk F. Upper limb
tendinitis and entrapment neuropathy in coal miners. Am J Ind Med.
2013;56(5):569–75.
12. Smidt N, van der Windt DAWM. Tennis elbow in primary care. Br Med J.
2006;333(7575):927–8.
13. Buchbinder R, Johnston RV, Barnsley L, Assendelft WJ, Bell SN, Smidt N.
Surgery for lateral elbow pain. The Cochrane Database Syst. Rev. 2011;(3):
CD003525.
14. Sanders TL Jr, Maradit Kremers H, Bryan AJ, Ransom JE, Smith J, Morrey BF.
The epidemiology and health care burden of tennis elbow: a population-
based study. Am J Sports Med. 2015;43(5):1066–71.
15. Walker-Bone K, Palmer KT, Reading I, Coggon D, Cooper C. Prevalence and
impact of musculoskeletal disorders of the upper limb in the general
population. Arthritis Rheum. 2004;51(4):642–51.
16. Hopkins C, Fu S-C, Chua E, Hu X, Rolf C, Mattila VM, et al. Critical review on
the socio-economic impact of tendinopathy. Asia-Pacific J Sports Med
Arthroscopy Rehabil Technol. 2016;4:9–20.
17. Coombes BK, Connelly L, Bisset L, Vicenzino B. Economic evaluation favours
physiotherapy but not corticosteroid injection as a first-line intervention for
chronic lateral epicondylalgia: evidence from a randomised clinical trial. Br J
Sports Med. 2015:bjsports-2015.
18. Coombes BK, Bisset L, Vicenzino B. Efficacy and safety of corticosteroid
injections and other injections for management of tendinopathy: a
systematic review of randomised controlled trials. Lancet. 2010;
376(9754):1751–67.
19. Devlin NJ, Appleby J. Getting the most out of PROMS. Putting health
outcomes at the heart of NHS decision making. London: King’s Fund; 2010.
20. Dawson J, Doll H, Fitzpatrick R, Jenkinson C, Carr AJ. The routine use of
patient reported outcome measures in healthcare settings. Br Med J.
2010;340:c186.
21. The B, Reininga IH, El Moumni M, Eygendaal D. Elbow-specific clinical rating
systems: extent of established validity, reliability, and responsiveness. J
Shoulder Elbow Surg. 2013;22(10):1380–94.
22. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. Ann Intern
Med. 2009;151(4):264–9.
23. Buchbinder R, Johnston RV, Barnsley L, Assendelft W, Bell SN, Smidt N.
Surgery for lateral elbow pain. Cochrane Libr. 2011;3(3).
24. Gonçalves Bradley DC, Gibbons C, Ricci‐Cabello I, Bobrovitz NJH, Gibbons EJ,
Kotzeva A, Alonso J, Fitzpatrick R, Bower P, van der Wees PJ, Rajmil L,
Roberts NW, Taylor RS, Greenhalgh J, Porter I, Valderas JM. Routine provision
of information on patient‐reported outcome measures to healthcare
providers and patients in clinical practice. Cochrane Database Syst. Rev.
2015;(4). Art. No.: CD011589.
25. Longo UG, Franceschi F, Loppini M, Maffulli N, Denaro V. Rating systems for
evaluation of the elbow. Br Med Bull. 2008;87:131–61.
26. Turchin DC, Beaton DE, Richards RR. Validity of observer-based aggregate
scoring systems as descriptors of elbow pain, function, and disability. J Bone
Joint Surg Am. 1998;80(2):154–62.
27. de Boer YA, Hazes JM, Winia PC, Brand R, Rozing PM. Comparative
responsiveness of four elbow scoring instruments in patients with
rheumatoid arthritis. J Rheumatol. 2001;28(12):2616–23.
28. ePROVIDE. PROQOLID Clinical Outcome Assessments Catalog [Available
from: https://eprovide.mapi-trust.org/about/about-proqolid].
29. Elmagarmid A FZ, Hammady H, Ilyas I, Khabsa M, Ouzzani M. Rayyan: a
systematic reviews web app for exploring and filtering searches for
eligible studies for Cochrane Reviews. In: Evidence-Informed Public
Health: Opportunities and Challenges. Abstracts of the 22nd Cochrane
Colloquium. 2014.
30. Valderas JM, Ferrer M, Mendivil J, Garin O, Rajmil L, Herdman M, et al.
Development of EMPRO: a tool for the standardized assessment of patient-
reported outcome measures. Value Health. 2008;11(4):700–8.
31. Schmidt S, Ferrer M, Gonzalez M, Gonzalez N, Valderas JM, Alonso J, et al.
Evaluation of shoulder-specific patient-reported outcome measures: a
systematic and standardized comparison of available evidence. J Shoulder
Elb Surg. 2014;23(3):434–44.
Evans et al. Sports Medicine - Open            (2019) 5:10 Page 12 of 13
32. Landis JR, Koch GG. The measurement of observer agreement for
categorical data. biometrics. 1977. p. 159-74.
33. Smith MV, Calfee RP, Baumgarten KM, Brophy RH, Wright RW. Upper
extremity-specific measures of disability and outcomes in orthopaedic
surgery. J Bone Joint Surg (Am Vol). 2012;94(3):277–85.
34. Freehill MT, Mannava S, Safran MR. Outcomes evaluation of the athletic
elbow. Sports Medicine and Arthroscopy. 2014;22(3):e25–32.
35. Badalamente M, Coffelt L, Elfar J, Gaston G, Hammert W, Huang J, et al.
Measurement scales in clinical research of the upper extremity, part 2:
outcome measures in studies of the hand/wrist and shoulder/elbow. J
Hand Surg. 2013;38(2):407–12.
36. Garin O, Herdman M, Vilagut G, Ferrer M, Ribera A, Rajmil L, et al.
Assessing health-related quality of life in patients with heart failure: a
systematic, standardized comparison of available measures. Heart Fail
Rev. 2014;19(3):359–67.
37. Polson K, Reid D, McNair PJ, Larmer P. Responsiveness, minimal
importance difference and minimal detectable change scores of the
shortened disability arm shoulder hand (QuickDASH) questionnaire. Man
Ther. 2010;15(4):404–7.
38. Smith-Forbes EV, Howell DM, Willoughby J, Pitts DG, Uhl TL. Specificity
of the minimal clinically important difference of the quick Disabilities of
the Arm Shoulder and Hand (QDASH) for distal upper extremity
conditions. J Hand Ther. 2016;29(1):81–8. https://doi.org/10.1016/j.jht.
2015.09.003.
39. Lowe A, Wessel J, Battié MC. Test-retest reliability, construct validity, and
responsiveness of a functional pain scale for tennis elbow. Department of
Physiotherapy, Edmonton Canada. 1999. Avaiable at http://www.
collectionscanada.gc.ca/obj/s4/f2/dsk1/tape9/PQDD_0021/MQ47060.pdf
40. Calvert M, Blazeby J, Revicki D, Moher D, Brundage M. Reporting quality
of life in clinical trials: a CONSORT extension. Lancet. 2011;378(9804):
1684–5.
41. Reeve BB, Wyrwich KW, Wu AW, Velikova G, Terwee CB, Snyder CF, et al.
ISOQOL recommends minimum standards for patient-reported outcome
measures used in patient-centered outcomes and comparative effectiveness
research. Qual Life Res. 2013;22(8):1889–905.
42. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of
cross-cultural adaptation of self-report measures. Spine. 2000;25(24):3186–91.
43. Beirer M, Friese H, Lenich A, Crönlein M, Sandmann GH, Biberthaler P,
Kirchhoff C, Siebenlist S. The Elbow Self-Assessment Score (ESAS):
development and validation of a new patient-reported outcome
measurement tool for elbow disorders. Knee Surg Sports Traumatol
Arthrosc. 2017 Jul 1;25(7):2230–6.
44. Makhni EC, Meadows M, Hamamoto JT, Higgins JD, Romeo AA, Verma NN.
Patient Reported Outcomes Measurement Information System (PROMIS) in
the upper extremity: the future of outcomes reporting? J Shoulder Elb Surg.
2017;26(2):352–7.
45. Andrews JR, St Pierre RK, Carson WG Jr. Arthroscopy of the elbow. Clin
Sports Med. 1986;5(4):653–62.
46. King GJ, Richards RR, Zuckerman JD, Blasier R, Dillman C, Friedman RJ, et al.
A standardized method for assessment of elbow function. Research
Committee, American Shoulder and Elbow Surgeons. J Shoulder Elbow
Surg. 1999;8(4):351–4.
47. Hudak PL, Amadio PC, Bombardier C, Beaton D, Cole D, Davis A, et al.
Development of an upper extremity outcome measure: the DASH
(disabilities of the arm, shoulder, and hand). Am J Ind Med. 1996;29(6):602–8.
48. Inglis AE, Pellicci PM. Total elbow replacement. J Bone Joint Surg.
1980;62(8):1252–8.
49. Sathyamoorthy P, Kemp G, Rawal A, Rayner V, Frostick S. Development and
validation of an elbow score. Rheumatology. 2004;43(11):1434–40.
50. Morrey B, Adams R. Semiconstrained arthroplasty for the treatment of
rheumatoid arthritis of the elbow. J Bone Joint Surg (Am Vol). 1992;74(4):479–90.
51. Broberg MA, Morrey B. Results of delayed excision of the radial head after
fracture. J Bone Joint Surg (Am Vol). 1986;68(5):669–74.
52. Nirschl RP, Pettrone FA. Tennis elbow. The surgical treatment of lateral
epicondylitis. J Bone Joint Surg (Am Vol). 1979;61(6):832–9.
53. Dawson J, Doll H, Boller I, Fitzpatrick R, Little C, Rees J, et al. The
development and validation of a patient-reported questionnaire to assess
outcomes of elbow surgery. J Bone Joint Surg Br Vol. 2008;90(4):466–73.
54. Overend TJ, Wuori-Fearn JL, Kramer JF, MacDermid JC. Reliability of a
patient-rated forearm evaluation questionnaire for patients with lateral
epicondylitis. J Hand Ther. 1999;12(1):31–7.
55. Beaton DE, Wright JG, Katz JN, Upper Extremity Collaborative G.
Development of the QuickDASH: comparison of three item-reduction
approaches. J Bone Joint Surg (Am Vol). 2005;87(5):1038–46.
56. Roles N, Maudsley R. Radial tunnel syndrome resistant tennis elbow as a
nerve entrapment. J Bone & Joint Surg Br Vol. 1972;54(3):499–508.
57. Pransky G, Feuerstein M, Himmelstein J, Katz JN, Vickers-Lahti M. Measuring
functional outcomes in work-related upper extremity disorders:
development and validation of the upper extremity function scale. J Occup
Environ Med. 1997;39(12):1195–202.
58. Verhaar J, Walenkamp G, Kester A, van Mameren H, van der Linden T.
Lateral extensor release for tennis elbow. A prospective long-term follow-up
study. J Bone Joint Surg (Am Vol). 1993;75(7):1034–43.
Evans et al. Sports Medicine - Open            (2019) 5:10 Page 13 of 13
